Odimma Therapeutics has joined the Paris Saclay Cancer Cluster (PSCC), the first European biocluster dedicated exclusively to oncology innovation.
As part of this initiative, Odimma Therapeutics will participate in the PSCC Innovation Forum 2024 taking place on February 5, 2024, under the patronage of President Emmanuel Macron.
The Paris Saclay Cancer Cluster brings together leading healthcare institutions, biotechnology companies, researchers, investors and industrial partners with the objective of accelerating next-generation cancer innovation across Europe.
Participation in the PSCC ecosystem further strengthens Odimma Therapeutics’ position within France’s emerging precision oncology and deeptech biotechnology landscape.
